- Home
- QDEL
as 09-16-2025 3:03pm EST
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.9B | IPO Year: | N/A |
| Target Price: | $40.17 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.05 - $49.45 | Next Earning Date: | 11-06-2025 |
| Revenue: | $2,741,600,000 | Revenue Growth: | -3.28% |
| Revenue Growth (this year): | -0.64% | Revenue Growth (next year): | 3.40% |
Latest QuidelOrtho Corporation News
QDEL Breaking Stock News: Dive into QDEL Ticker-Specific Updates for Smart Investing
Insider Monkey
7 days ago
RBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy Rating
Argus Research
3 months ago
QDEL: Rating increased to a HOLD
Zacks
3 months ago
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
Zacks
3 months ago
Why QuidelOrtho (QDEL) is a Top Growth Stock for the Long-Term
Zacks
3 months ago
Should Value Investors Buy QuidelOrtho (QDEL) Stock?
StockStory
3 months ago
QDEL Q1 Earnings Call: Cost Savings and Tariff Mitigation Anchor 2025 Outlook
StockStory
3 months ago
1 Stock Under $50 Worth Your Attention and 2 to Approach with Caution
Argus Research
3 months ago
QDEL: Rating increased to a HOLD
Compare QDEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QDEL QuidelOrtho Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.